Screener
Monte Rosa Therapeutics, Inc. GLUE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s net income?
- Monte Rosa Therapeutics, Inc. (GLUE) reported net income of -$43.4M in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s net income changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s net income decreased by 253.0% year-over-year, from -$12.3M to -$43.4M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s net income has grown at a -19.5% compound annual growth rate (CAGR), from -$73.96M to -$38.63M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Monte Rosa Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude